

ACE inhibitors (ACEIs), in diabetes (*continued*)

- FACET study, 74, 143, 270t
- new-onset diabetes, 98t, 140-142, 216
- UKPDS study, 95, 115-118, 118t
- diuretics vs, 91, 216, 271t
 - ACCOMPLISH, 133-135, 135t, 136, 270t-271t
 - ALLHAT, 271t
 - ANBP 2, 271t
 - ASCOT, 271t
- diuretics with, 67, 72, 83, 135, 145, 151, 228
 - combination medications, 233t
- dosage, 111t, 135, 138
- in elderly patients, 138, 139, 222t, 225
- heart failure and, 109-112, 216
 - HOPE and HOPE-TOO studies, 75, 112-114
- hyperglycemia risk, 101
- indications for, 145, 218t-219t, 222t, 224
 - in heart failure, 109-112
 - specific or compelling reasons, 67, 68t, 71, 112, 218t-219t
- as initial therapy, 60, 61t, 70, 72, 73t, 112, 130, 135, 145, 217, 227, 267
 - adding a diuretic to, 228
 - cautions for, 222t
 - combination therapy with, 112, 145, 217, 232
 - ESH/ESC recommendation, 70, 73t, 130
 - JNC 7 recommendation, 73t
 - in special situations, 71, 73t, 112
- insulin resistance and, 139
- monotherapy with, 135, 227
- myocardial infarction and, 112, 115, 116, 117, 216, 227, 272
- physiologic effects, 109, 110, 111t, 226t
- in pregnancy, contraindication for, 138, 220t
- renal disease and, 138-143, 216, 222t, 261, 269
- renovascular function/disease, 138-143, 179, 216, 261
 - monitoring for, 138, 139
- side effects, 109, 111t, 137-138
 - cough, 137
 - loss of taste, 138
- specific or compelling reasons for use, 67, 68t, 71, 112, 218t-219t
- stroke protection with, 69, 72, 74
- tolerability, 76
- trials and studies, 112-137
 - ACCOMPLISH, 133-135, 135t, 136, 270t-271t
 - ADVANCE, 142-143
 - ALLHAT, 66, 119-130, 126-129, 270t-271t
 - ANBP 2, 130-133, 132, 271t
 - CALM, 154
 - CAPPP, 114-115, 116, 117, 139, 270t
 - HOPE, 75, 111-112, 139
 - HOPE-TOO, 113-114, 114
 - ONTARGET, 160, 271t
 - PROGRESS, 72, 105-107, 133, 134

ACE inhibitors (ACEIs), trials and studies (*continued*)

- STOP-Hypertension-2, 74, 119, 120, 121t, 122, 264, 270t-271t
 - summary of, 135-137
 - UKPDS, 115-118, 270t
- Acebutolol (Sectral), 182t
- action mechanisms, 181-183
 - average blood pressure change in TOMHS study, 61t
 - dosage, 182t, 184
- ACEIs. See *ACE inhibitors (ACEIs)*.
- Aceon. See *Perindopril*.
- Action in Diabetes and Vascular Disease: Preterax and Diamicon MR Controlled Evaluation (ADVANCE) Trial, 142-143
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, 65
- Adalat CC. See *Nifedipine*.
- Adrenalectomy, 17
- Adrenergic blockers. See *α_1 -Blockers; β -Blockers; Peripheral adrenergic inhibitors*.
- ADVANCE trial, 142-143
- Aerobic exercise, 43
- African American Study of Kidney Disease and Hypertension (AASK), 75, 145, 179, 186, 270t. See also *Black patients*.
- Age, initial drug selection and. See also *Elderly patients*.
- Albuminuria, 74, 154
- Alcohol intake/moderation, 32t, 43, 45-46
 - recommended intake limits, 43, 45-46
- Aldactazide, 235t
- Aldactone (spironolactone), 81t
- Aldomet. See *Methyldopa*.
- Aldosterone, 110
 - ACE inhibitors and, 109
 - visceral fat and, 31
- Aldosterone antagonists, 81t, 82, 232. See also *Renin-angiotensin-aldosterone (RAAS) inhibitor*.
- high-potassium diet for, 40
 - indications for, 67, 68t, 218t, 225
 - side effects, 232
 - specific or compelling reasons for use, 67, 68t, 232
 - tolerability, 90
- Aldosteronism, resistant hypertension and, 244t
- Aliskiren (Tekturna), 60, 161-163, 162t, 236
- ALTITUDE trial, 163, 271t
- combination therapy, 60, 161, 236
 - contraindications/cautions for, 265
 - dosage, 161, 162t
- Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE), 163, 271t
- ALLHAT (Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial), 66-67, 119-130, 126-129
 - α_1 -blockers and cardiac events on, 123, 201
 - ACEIs in, 66, 119-130, 126-129, 270t-271t
 - agents compared in, 123

ALLHAT (Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial) (*continued*)

- black population in, 66-67, 123, 125
- blood pressure control on, 57, 66, 123-125, 124t, 265
- blood pressure monitoring in, 26
- cardiovascular events on, 72-74, 108, 123, 125, 126-129, 140, 141, 177
- CCBs in, 167, 168, 177
- coronary heart disease events, 125, 126, 129
- criticism of, 66
- diabetes, new-onset, 94-95, 98t, 99, 99t, 140, 142, 154
- diabetic population in, 123
- diuretic outcomes, 66
- diuretics and cholesterol levels, 91, 93t
- diuretics and glucose metabolism, 96t
- diuretics vs ACE inhibitors on, 271t
- doxazosin on, 123
- drugs compared in, 123, 270t
- follow-up (8- to 13-year), 130
- heart failure on, 125, 127, 129, 168, 271t
- initial drugs, choice/comparison of, 66, 123
- morbidity/mortality outcomes data, 125, 126-129, 269, 270t-271t
- number of patients in, 66, 123
- protocol design, 66, 119-123
- renal disease and, 102, 103, 104
- strokes on, 66, 125, 128, 129, 270t-271t
- summary of outcomes, 124, 125, 126, 216, 221, 264, 269, 270t-271t, 272
- trial design, 119-123

Allopurinol, 224

α_1 -Blockers, 199-201, 202t, 226t. See also *β -Blockers with vasodilating properties; specific drugs.*

- action mechanism, 199, 200
- agents, specific, 199, 202t
- ALLHAT trial, 66, 123, 201, 271t
- angina and, 222t
- cardiac events and, 123, 216, 224
- contraindications, 201, 218t
- diuretics vs, 228, 271t
- dosage, 200, 202t
- indications for, 218t, 222t
 - as add-on therapy, 72
 - in special situations, 71, 224
- as initial drug, 73t
 - ESH/ESC recommendation, 73t
 - not recommended for, 66, 72, 76, 267
- lipid levels and, 201
- nonselective, 199
- physiologic effects, 202t, 226t
- for prostatic hypertrophy, 86, 222t
- side effects, 76, 199-200, 202t

Altace. See *Ramipril.*

ALTITUDE, 163, 271t

Ambulatory blood pressure monitoring (ABPM), 25-27

Amiloride (Midamor), 81t

Amiloride with hydrochlorothiazide (Moduretic), 79, 235t

Amlodipine (Norvasc), 165, 166t. See also *Calcium channel blockers (CCBs).*

- AASK study, 179, 186
- action mechanisms, 165, 166t, 167
- aliskiren with, 161
- ALLHAT trial, 66, 123, 126-129, 140, 141, 167, 168, 269, 269
- ASCOT trial, 177-179, 178t
- cardiovascular/coronary heart disease events, 140, 141, 269
- cholesterol and, 91
- dosage, 166t
- FACET study, 74, 143
- IDNT study, 155-157, 156
- TOMHS study, blood pressure change on, 61t
- VALUE trial, 167

Amlodipine with atorvastatin (Caduet), 235t

Amlodipine with benazepril (Lotrel), 234t

Amlodipine with olmesartan medoxomil (Azor), 234t

Amlodipine with olmesartan medoxomil and hydrochlorothiazide (Tribenzor), 234t

Amlodipine with valsartan (Exforge), 234t

Amlodipine with valsartan and hydrochlorothiazide (Exforge HCT), 234t

ANBP 2 (Australian National Blood Pressure) study, 130-133, 132, 271t

- criticism of, 131
- diabetes, new-onset, 98t
- drugs compared, 271t
- endpoints and results, 132, 271t
- morbidity/mortality outcome data, 131, 132, 271t
- trial description, 130-131

Angina pectoris

- in ALLHAT, 129
- α_1 -blockers and, 185
- β -blockers and, 222t
- CCBs in, 222t
- drug indications and contraindications in, 218t, 222t

Angioedema

- ACE inhibitors and, 137
- ARBs and, 151

Angioplasty, SHEP study, 100, 263

Angiotensin I, 109, 110, 161

Angiotensin II, 109, 110

- ACE inhibitors and, 109, 138
- renin inhibitors and, 161

Angiotensin II receptor blockers (ARBs). See *ARBs.*

Angiotensin-converting enzyme inhibitors. See *ACE inhibitors (ACEIs).*

Anglo-Scandinavia Cardiac Outcomes Trial. See *ASCOT.*

Antidrenergic agents. See *α_1 -Blockers; β -Blockers; Central agonists; Peripheral adrenergic inhibitors.*

Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial. See *ALLHAT.*

- Appropriate Blood Pressure Control in Diabetes. See *ABCD study*.
- Apresoline. See *Hydralazine*.
- ARBs (angiotensin II receptor blockers), 147-160, 148t, 226t. See also *specific drugs*.
- ACE inhibitors with, 160
 - action mechanisms/sites, 110, 147
 - age and race in choice of, 222t
 - agents approved in the United States, 147, 148t
 - aliskiren with, 161
 - β -blockers vs, 271t, 272
 - in black patients, 150, 222t, 223
 - cardiovascular morbidity and mortality and, 229, 272
 - CCBs with, 150, 228, 234t
 - combination therapy, 62, 67, 148t, 149-151
 - combination medications, 150, 233t-234t
 - contraindications and cautions, 76, 219t, 222t
 - diabetes, 151, 153-158, 158, 179, 217, 222t
 - new-onset diabetes, 98t, 154, 216, 229
 - prevention, 158
 - diuretics with, 85, 108, 149-150, 151, 228
 - combination medications, 233t
 - dosage, 148t, 149
 - in fixed-dose combinations, 150
 - in two-drug therapy, 151
 - in elderly patients, 151-152, 222t, 225
 - heart failure, 67
 - indications for, 147, 149-151, 218t-219t, 222t, 224
 - specific indications, 67, 68t, 71, 152-153, 218t-219t
 - heart failure, 152
 - left ventricular hypertrophy, 152-153, 153t, 157
 - as initial therapy, 70, 73t, 130, 149, 217, 222t, 227, 267
 - adding a diuretic to, 149-150, 228
 - combination therapy, 151, 217
 - for diabetics, 179
 - in diabetics, 217
 - ESH/ESC recommendation, 73t, 130
 - JNC 7 recommendation, 73t
 - in special situations, 71, 152-153, 158, 179, 218t-219t
 - monotherapy with, 227
 - physiologic effects, 147-149, 148t, 226t
 - in pregnancy, contraindication for, 138, 220t
 - renal disease and, 261, 269
 - side effects, 148t, 151
 - specific or compelling reasons for use, 67, 68t, 71, 149-150, 152-153, 218t-219t
 - stroke and, 229
 - tolerability, 76, 151, 157
 - trials and studies, 152-160
 - CHARM, 152
 - ELITE 2, 152
 - IDNT, 155-157, 156
- ARBs (angiotensin II receptor blockers), trials and studies (*continued*)
- IRMA 2, 157, 158
 - LIFE, 152-153, 153t
 - ONTARGET, 160, 271t
 - RENAAL, 74, 149, 154-155
 - SCOPE, 158-159
 - TROPHY, 22
 - Val-HeFT, 152
 - VALUE, 95, 140, 159, 160t
- Arrhythmias, CCBs indicated for, 167
- ASCOT (Anglo-Scandinavia Cardiac Outcomes Trial), 69-70, 72, 167, 176-179, 178t, 185, 216, 271t
 - blood pressure lowering arm (ASCOT-BPLA), 176-179, 178t
 - diabetes, new-onset, 98t, 140-142, 176-179
 - endpoints and results, 264-265, 271t
 - morbidity/mortality outcome data, 185, 216, 271t
- Aspirin, for CV protection, 173
- Asthma
 - β -blockers and, 183, 187, 188t, 222t, 224
 - central agonists in, 209
- Atacand (candesartan cilexetil), 147, 148t
- Atacand HCT (candesartan cilexetil with HCTZ), 106t, 150, 233t
- Atenolol (Tenormin), 182t, 221
 - action mechanism, 181-183, 182t
 - ALLHAT study, 123
 - ASCOT trial, 167, 177-179, 178t
 - LIFE study, 153, 153t
 - UKPDS study, 115-118
- Atenolol with chlorthalidone (Tenoretic), 106t, 192, 234t
- Atherosclerosis, verapamil and (VHAS study), 270t
- Atorvastatin, with amlodipine (Caduet), 235t
- Augmentation index, 29
- Australian National Blood Pressure Study (ANBP 2), 130-133, 132, 271t
- Autoimmune disorders, central agonists and, 209
- Avalide (irbesartan with HCTZ), 106t, 150, 233t
- Avapro. See *Irbesartan*.
- Azilsartan medoxomil (Edarbi), 147, 148t, 149, 217
- Azilsartan medoxomil with chlorthalidone (Edarbyclor), 106t, 108, 150, 233t
- Azor, 234t
- Baroreceptors, 211, 248
 - stimulation by pulse generator, 250, 251
- Beer, recommended intake limit, 43
- Benazepril (Lotensin), 111t
- Benazepril/amlodipine, 133-135, 135t, 136, 232
- Benazepril/HCTZ, 133-135, 135t, 136
- Benazepril with thiazide (Lotensin HCT), 106t, 233t
- Bendroflumethiazide with nadolol (Corzide), 192, 234t
- Benicar (olmesartan medoxomil), 147, 148t
- Benicar HCT, 106t, 150, 233t
- Benson relaxation response technique, 44, 45t, 46

β -Blockers, 181-192, 182t, 226t. See also *β -Blockers with vasodilating properties; specific drugs*.
 ACE inhibitors vs, 114-115, 119, 121t, 270t
 action mechanisms, 181-183, 182t
 agents, specific, 182t, 194t
 in ALLHAT trial, 123
 ARBs vs, 271t, 272
 asthma and, 183, 187, 188t, 222t, 224
 in black patients, 222t, 223
 cardioselectivity of, 181-183, 182t
 cardiovascular morbidity and mortality and, 76, 185-187, 191, 217, 262-263
 CCBs vs, 167, 175, 186, 216
 CCBs with, 167
 choice of agent, factors in, 184
 combination therapy, 185, 192, 232, 270t-271t
 combination medications, 234t
 compared with other antihypertensive medications, 270t-271t
 contraindications and cautions, 183, 187, 218t, 222t, 224
 use as initial therapy, 72, 187, 192
 in diabetes, 190, 229
 LIFE study, 186, 271t
 diuretics vs, 271t
 diuretics with, 85, 192, 232, 270t-271t
 combination medications, 234t
 dosage, 182t, 184
 effectiveness of, 184-185
 in elderly patients, 185, 262-263
 hyperglycemia risk, 101
 hypoglycemia and, 191
 indications for, 184-185, 186-187, 191-192, 218t-219t, 222t
 heart disease and previous MI, 185-186, 186t, 224
 in special situations, 70, 71, 76, 184-185, 187, 192, 217, 218t-219t, 224
 as initial therapy, 60, 61t, 73t, 267
 combination therapy, 232
 contraindication/caution for, 70, 187, 192, 267-269
 ESH/ESC recommendation, 73t
 JNC 7 recommendation, 73t
 in special situations, 71, 73t, 217, 222t, 267
 with intrinsic sympathomimetic action (ISA), 182t, 183-184
 lipid levels and, 189t, 190, 220, 224-225
 lipid solubility, 184
 for migraine headaches, 222t
 monotherapy with, 191
 myocardial infarction and, 68t, 69, 224, 227, 263-264
 physiologic effects, 181-184, 182t, 226t
 secondary to, 190-191
 quality-of-life measures, 190
 renal blood flow changes, 191
 renal disease progression, reduced with, 269

β -Blockers (*continued*)
 side effects, 187-190, 188t-189t
 bradycardia, 187, 188t
 cardiac, 187
 central effects, 184, 190
 cold hands/Raynaud's phenomenon, 188t
 dyspnea/asthma flare-up, 187, 188t
 fatigue, 188t, 190
 hypoglycemia, 191
 insomnia/bizarre dreams, 188t
 pulmonary, 187, 188t
 renal blood flow changes, 191
 sexual dysfunction, 188t
 specific or compelling reasons for use, 67, 68t, 187, 192, 218t-219t
 trials and studies, 185
 AASK, 75, 186
 ASCOT, 177, 185, 186, 187, 216
 CAPPP, 114-115, 116, 117
 HAPPHY, 185
 LIFE study, 271t
 MAPHY, 185
 MRC, 185, 186, 271t
 STOP-Hypertension-2, 119, 120, 121t, 185, 264, 271t
 TOMHS, 190
 UKPDS, 115-118, 118t, 186, 192
 types of, 181-183, 182t
 with vasodilating properties, 71, 72, 76, 183-187, 194t
 β -Blockers with vasodilating properties, 193-197, 194t. See also *β -Blockers; specific drugs*.
 as add-on therapy, 76, 195, 228
 agents, specific, 193, 194t
 in black patients, 296
 combined with diuretic, 85
 contraindications and cautions, 196
 dosage, 193-195, 194t
 effectiveness of, 193
 in elderly patients, 196
 GEMINI study, 197
 indications for, 71, 195
 physiologic effects, 193, 194t, 195t
 side effects, 193, 195
 Biofeedback/relaxation programs, 44, 45t, 46
 Bisoprolol with thiazide (Ziac), 234t
 Bisoprolol (Zebeta), 182t, 192
 action mechanism, 181-183, 182t
 cardiovascular events and, 224
 side effects, 187
 Black patients
 AASK study, 75, 145, 179, 186
 ACE inhibitors in, 139, 145, 222t, 223
 in ALLHAT trial, 66-67, 123, 125

Black patients (*continued*)
 ARBs in, 150, 222t, 223
 β -blockers in, 222t, 223
 β -blockers with vasodilating properties in, 196
 CCBs in, 76, 85, 145, 167, 168, 222t, 223
 combination therapy for, 230
 diuretics in, 60, 85, 222t, 223
 drug selection for, 60-62, 223, 226t
 physiologic characteristics of drugs, 226t
 preferred initial therapy, 60, 223
 nondippers, LVH and, 26
 sodium restriction/salt sensitivity in, 27

Blocadren. See *Timolol*.

Blood pressure (BP)
 140/90 mm Hg level, 17, 19, 21t, 30
 ambulatory monitoring (ABPM), 25-27
 cardiovascular risk and, 19-21, 20, 55t
 circadian rhythm of, 26
 coffee/caffeine intake and, 46-47
 control
 in ALLHAT trial, 57, 66, 123-125, 124t, 265
 in CONVINCE study, 125, 265
 trends in, 260, 272-275
 diastolic. See *Diastolic blood pressure (DBP)*.
 goal levels, 59, 62, 65, 275
 diabetic patients, 62, 173
 elderly patients, 62, 265
 lower limit for (J-curve hypothesis), 64-65, 273-275
 home monitoring, 26-27, 63
 hypertension, definition of, 21t
 lowering. See also *Management of hypertension*.
 acceptable amount of, 273-275
 as basis of drug benefits, 70, 75, 77-78, 216, 257
 benefits of, 257-258, 267, 272-275
 with lifestyle modifications, 31, 36, 36t, 42, 49
 as more important than specific drug, 70, 72-73, 75, 77-78
 nondippers, 26
 normal, 21t
 optimal adult, JNC 7 recommendation, 21t
 optimal, normal, high-normal classification, 23
 risk stratification and, 53t, 55t
 sodium intake and, 37
 systolic. See *Systolic blood pressure (SBP)*.
 thresholds for hypertension, 19, 21t, 27t, 31

Blood Pressure Lowering Treatment Trialists Collaboration, 69

Body weight, ideal, 32-33, 33t. See also *Obesity*; *Weight loss*.
 calories needed to maintain, 34, 34t

Borderline
 hypertension, 20
 ISH, 20

Bradycardia
 β -blockers and, 187, 188t, 222t
 drug contraindications for, 218t

Bradykinin levels
 ACE inhibitors and, 109, 110
 ARBs and, 147

Breathing, machine to regulate, 44

British Hypertension Society, 107

Bumetanide (Bumex), 80t, 107

Bumex. See *Bumetanide (Bumex)*.

Bystolic. See *Nebivolol*.

C & W (Coope and Warrender) study, 262t

Caffeine intake, 46-47

Calan. See *Verapamil*.

Calcium
 dietary intake/supplementation, 32t, 39, 45
 hypercalcemia, diuretic-induced, 87t, 102

Calcium channel blockers (CCBs), 165-179, 166t, 226t. See also
Dihydropyridine CCBs; *Nondihydropyridine CCBs*; *specific drugs*.
 ACE inhibitors vs, 143-145, 167, 168, 175, 228, 269, 270t
 ALLHAT trial, 66, 119-130, 167, 168, 269
 STOP-Hypertension-2 study, 119, 120, 121t, 122, 177, 264, 270t-271t
 ACE inhibitors with, 145, 168-169, 217, 228, 232, 270t-271t
 ACCOMPLISH, 133-135, 135t, 136, 168, 232, 270t-271t
 ASCOT, 69-70, 140, 167, 176-179, 178t, 264-265, 271t
 combination medications, 234t
 INVEST, 270t
 action mechanisms, 165, 166t, 167
 adverse reactions, 165, 166t, 173-174, 176
 agents available, 165, 166t
 aliskiren with, 161
 in angina patients, 222t
 ARBs vs, 167
 ARBs with, 228, 234t
 β -blockers vs, 167, 175, 186, 216
 β -blockers with, 167
 in black patients, 85, 145, 167, 168, 222t, 223
 cardiovascular morbidity/mortality and, 69, 168-179, 174, 216, 221, 228, 272
 cholesterol and, 91
 combination therapy, 62, 167, 232, 270t-271t
 combination medications, 230-231, 234t
 outcome data, 270t-271t
 three-drug combinations, 230, 234t
 compared with other antihypertensive medications, 270t-271t
 contraindications and cautions, 165, 167, 222t
 coronary heart disease (CHD) and, 174, 176
 diabetes and, 168
 ABCD study, 74, 143-144, 144t, 270t
 diabetes, new-onset, 95, 98t

Calcium channel blockers (CCBs), diabetes and (*continued*)

- FACET study, 74, 143, 270t
- HOT trial, 170-173, 172t
- SHEP study, 170
- Syst Eur trial, 67-69, 169-170, 264
- VALUE trial, 95, 140, 159, 160t, 167
- dihydropyridines, 165, 166t, 167-169
- diuretics vs., 175, 216, 270t, 272
- diuretics with, 85, 168
- dosage, 166t
- effectiveness of, 167-168, 179
- in elderly patients, 76, 85, 159, 167, 168, 169, 170, 222t, 225, 263
- hyperglycemia risk, 101
- indications for, 73t, 167, 179, 218t-219t, 222t
 - in black patients, 76, 222t
 - contraindications and cautions, 165, 167, 222t
 - in elderly patients, 76, 85, 170, 179, 222t
 - in special situations, 67, 68t, 71, 137, 168
 - summary of, 179
- as initial therapy, 60, 61t, 70, 73t, 130, 137, 170, 217, 227, 267
- combination therapy, 232
- ESH/ESC recommendation, 70, 73t, 130, 170
- JNC 7 recommendation, 73t
- in specific situations, 73t, 137, 179, 222t
- long-acting formulations, 167, 174
- monotherapy with, 167, 168, 227
- myocardial infarction and, 272
- nondihydropyridines, 165, 166t, 167
- physiologic effects, 165, 166t, 226t
- renal disease and, 269
- short-acting formulations, 167
- side effects, 166t, 173-174
- specific or compelling reasons for use, 67, 68t, 137
- stroke and, 75, 176, 228, 272
- Syst Eur, 264
- treatment program summary, 179
- trials and studies, 169-179
 - AASK, 75, 179, 270t
 - ACCOMPLISH, 133-135, 135t, 136, 168, 270t-271t
 - ALLHAT, 66, 119-130, 168, 177, 270t
 - ASCOT, 69-70, 140-142, 167, 176-179, 178t, 216, 264-265, 271t
 - comparative trials in hypertension, 175-179
 - HOT, 170-173, 171t, 172t
 - INSIGHT, 175, 176, 270t
 - INVEST, 175-176, 270t
 - NORDIL, 74, 175, 176, 270t
 - SHEP, 170
 - STOP-Hypertension-2, 119, 120, 121t, 122, 264, 270t-271t
 - Syst Eur, 169-170, 264
 - VALUE, 159, 160t, 167
- types of, 165
- CALM (Candesartan and Lisinopril Microalbuminuria) study, 154
- Calories, 34
 - expenditure for weight loss, 34, 34t
 - expenditure in various activities, 35t, 44
 - needed to maintain ideal weight, 34, 34t
- Candesartan and Lisinopril Microalbuminuria (CALM) study, 154
- Candesartan cilexetil (Atacand), 147, 148t
 - CALM study, 154
 - dosage, 148t, 149
 - SCOPE study, 158-159, 264
- Candesartan cilexetil with HCTZ (Atacand HCT), 106t, 150, 233t
- Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) trial, 98t, 152
- Capoten (captopril), 111t
- CAPPP. See *Captopril Prevention Project*.
- Captopril (Capoten), 111t
 - in CAPPP, 114-115
 - UKPDS study, 115-118
- Captopril Prevention Project (CAPPP), 114-115, 116, 117, 139, 270t
 - CV event reduction, 69, 74
 - diabetes, new-onset, 98t, 115
 - drugs compared, 114
 - morbidity/mortality outcome data, 270t
 - trial description, 114-115
- Cardiac arrhythmias, nondihydropyridines indicated for, 167
- Cardiac function, drug indications and contraindications, 218t, 226t
- Cardiovascular (CV) risk. See also *Congestive heart failure; Heart entries; Left ventricular entries*.
 - α_1 -blockers and, 123, 216
 - ACE inhibitors and, 69, 112, 115, 116, 117, 125, 126-129, 143-144, 144t, 269
 - alcohol intake and, 43
 - aspirin and, 173
 - beneficial effects of long-term therapy on, 57-60, 58
 - β -blockers and, 185-187, 186t, 191, 217
 - blood pressure and, 17, 19-21, 20, 48, 53t, 55t
 - CCBs and, 69, 168-179, 216, 221
 - diabetes and, 54-57
 - diuretics and, 65-66
 - in elderly, trial outcomes, 268t
 - Framingham risk calculator, 52, 53t
 - hypertension and, 17, 19-21, 20
 - J-curve hypothesis, 64-65
 - lifestyle modifications and, 32t, 33, 38, 43. See also *Lifestyle modifications*.
 - pulse pressure and, 24
 - smoking and, 46
 - systolic blood pressure and, 19-21, 20
- Cardiovascular morbidity and mortality, 57-60, 58, 269-272, 270t-271t.
 - See also *specific drugs and conditions*.
 - ACCOMPLISH trial, 134-135, 135t, 136, 168, 232, 270t-271t

Cardiovascular morbidity and mortality (*continued*)

- ACE inhibitors and, 115, 116, 117, 125, 126-129, 140, 141
- ALLHAT trial, 72-74, 108, 123, 125, 126-129, 140, 141, 168, 270t-271t
- antihypertensive drug treatment, beneficial effects of, 57-60, 58, 253-270
- ARBs and, 229
- β -blockers and, 185-186, 186t, 217
- CAPPP, 115, 116, 117
- CCBs and, 69, 221
- comparative outcome data for antihypertensive medications, 270t-271t
- decline in, 253-261, 262t
- decrease in, associated with hypertension treatment, 253-261
- diuretics and, 65-66, 102, 103, 104, 269
- drug treatment and, 57-60, 58, 267-272, 270t-271t
- in elderly, trial data, 268t
- FACET trial, 74, 143, 270t
- HOT trial, 57, 69, 172-173
- RAAS inhibitors and, 69
- summary of trial results, 267-272, 270t-271t

Cardizem CD, 165, 166t. See also *Diltiazem*.

Cardizem LA, 165, 166t. See also *Diltiazem*.

Cardura. See *Doxazosin*.

Carotid sinus, 250, 251

Carvedilol (Coreg, Coreg CR), 193, 194t, 195, 196-197

- combined therapy, 228
- in congestive heart failure, 196-197, 224
- dosage, 194t
- GEMINI study, 197
- indications and contraindications for, 218t, 228

Catapres. See *Clonidine*.

Catecholamines

- alcohol and, 43
- initial evaluation and, 28t
- nicotine and, 46

CCBs. See *Calcium channel blockers (CCBs)*.

Central agonists, 207-210, 208t, 226t. See also *specific drugs*.

- action mechanisms, 207
- agents, specific, 207, 208t
- in combination with diuretics, 207
- diabetes and, 209
- dosage, 208t
- effectiveness of, 207
- indications for, 209-210
- physiologic effects, 207, 208t, 226t
- side effects, 207-209, 208t

Central aortic pressure (CAP), 29

Central nervous system, β -blockers and, 184, 190

Cerebrovascular incidents. See *Stroke; Transient ischemic attacks*.

CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) trial, diabetes, new-onset, 98t, 152

CHF. See *Congestive heart failure (CHF)*.

Children, hypertension diagnosis in, 29

Chlorothiazide (Diuril), hemodynamic effects, 83

Chlorthalidone, 79, 80t, 108. See also *ALLHAT; Diuretics*.

- ALLHAT trial, 123, 126-129, 141, 269, 269
- blood pressure change in TOMHS study, 61t
- cardiovascular/coronary heart disease events, 216, 269
- CCBs vs., 175
- dosage, 225
- duration of action, 79
- hyperuricemia/gout with, 102
- hypokalemia and, 88
- vs HCTZ, 108

Cholesterol level. See also *Hyperlipidemia; Hypertriglyceridemia; Lipid levels*.

- α_1 -blockers and, 201
- diuretics and, 90-91, 92t-93t, 94
- effects of specific antihypertensive drugs on, 226t

Chronic obstructive pulmonary disease (COPD), 187

Cialis (tadalafil), 86

Circadian rhythm of blood pressure, 26

Classification of hypertension, 21-23, 21t

Clinical trials. See *Trials and studies*.

Clonidine (Catapres), 207, 208t, 209. See also *ALLHAT; Central agonists*.

- in ALLHAT trial, 123
- dosage, 208t
- duration of action, 209
- as patch (Catapres-TTS), 208t, 209
- side effects, 208t, 209

Clonidine with chlorthalidone (Clorpres), 106t

Clorpres, 106t

Coarctation of aorta, resistant hypertension and, 245t

Coffee consumption, blood pressure and, 46-47

Combination medications (fixed combinations), 106t, 230-231, 233t-235t

Combination therapy. See *Drug treatment of hypertension, combination therapy*.

Congestive heart failure (CHF). See also *Cardiovascular (CV) risk; Heart disease*.

- β -blockers with vasodilating properties and, 196-197
- decline in, 256, 259-260, 259t
- in elderly patients, treatment outcomes, 262t
- hypertension as factor in, 260
- long-term antihypertensive drug treatment and, morbidity reduction with, 58, 59, 256

Controlled Onset Verapamil Investigation of Cardiovascular End Points. See *CONVINCE trial*.

CONVINCE trial, 57, 265

- blood pressure control in, 57, 125, 265

Coreg/Coreg CR. See *Carvedilol*.

Corgard (nadolol), 182t

Coronary artery bypass graft, SHEP study, 100

Coronary heart disease (CHD)

- ACE inhibitors and, 125, 126, 222t, 224
- on ALLHAT, 66, 125, 126, 129, 168, 270t

Coronary heart disease (CHD) (*continued*)
 blood pressure elevation and risk of, 19-20, 20
 blood pressure reduction and, 64
 CCBs and, 174, 176
 decline in, 253, 254, 256, 256t, 257t
 diuretics and, 216, 228
 drugs indications in, 67, 68t, 224
 in elderly patients, treatment outcomes, 262t
 initial drug selection and, 224
 initiation of hypertension treatment and, 51
 morbidity and mortality from, 262t
 ABCD study, 144, 144t
 ALLHAT, 72-74, 125, 126, 168, 270t
 reduced with antihypertensive drug treatment, 58, 253, 254, 255t, 256, 256t, 257t
 SHEP, 95, 100, 261
 as risk factor, hypertension treatment initiation and, 51
 Corzide, 192, 234t
 Cost
 of diuretics, 76
 of drug therapy, 63, 76, 221, 269
 Cough, 137, 151
 Covera. See *Verapamil*.
 Cozaar. See *Losartan*.
 Cushing's syndrome, resistant hypertension and, 245t

DASH (Dietary Approaches to Stop Hypertension) diet, 33, 37-38, 38t, 42
 DASH (Dietary Approaches to Stop Hypertension) study, 37-38, 42
 DBP. See *Diastolic blood pressure (DBP)*.
 Definitions
 of hypertension, 19, 21, 21t
 of isolated systolic hypertension (ISH), 20
 Demadex (torsemide), 80t, 107
 for vasodilator-induced fluid accumulation, 213
 Denervation (renal denervation), 241, 248-250, 250, 275
 Depression
 central agonists and, 207
 reserpine and, 204
 Diabetes. See also *STOP-Hypertension-2*.
 ACE inhibitors in, 112-114, 140-142, 154, 158, 179, 222t, 228
 ARBs in, 151, 153-158, 179, 222t
 as initial therapy, 179
 β -blockers in, cautions for, 183
 blood pressure control, importance of, 172-173
 blood pressure goal in, 62, 173
 cardiovascular risk and, 64-67
 CCBs in, 69-70, 168, 169-170, 228
 central agonists in, 209
 combination therapy in, 228
 contraindicated drugs, 183, 219t
 as coronary heart disease (CHD) equivalent, 54

Diabetes (*continued*)
 diuretics and, 94-101, 217
 drug therapy in, 54-57, 179, 227, 228
 drug selection for initial therapy, 179
 specific indications and cautions, 67, 68t, 227
 in elderly patients, 263
 hypokalemia and, 88
 increase in, 253-256
 insulin resistance, diuretics and, 87t, 91-101
 nephropathy
 ACE inhibitors and, 222t
 ARBs and, 149, 222t
 IDNT trial, 74, 271t
 IRMA-2 study, 74, 157, 158
 new-onset, 94-101, 96t-97t, 98t, 140-142, 154
 ACE inhibitors and, 115, 140-142, 154, 216
 in ALLHAT, 94-95, 99, 140, 154
 ARBs and, 154, 216, 229
 in ASCOT, 140-142
 β -blockers and, 190, 229
 CCBs and, 176
 in INVEST, 270t
 RAAS inhibitors and, 75
 in VALUE, 140, 154
 obesity and, 253
 obesity and body shape in, 31-32
 prevention, 142
 RAAS inhibitors and, 75
 references (readings) on, 286-287
 as risk factor, treatment initiation and, 51
 studies
 ABCD, 74, 143-144, 144t
 ACCORD, 65
 ADVANCE, 142-143
 ALTITUDE, 163, 271t
 CALM, 154
 CAPPP, 74, 114-115, 116, 117, 270t
 FACET, 74
 GEMINI, 197
 HOPE, 75, 111-112
 HOPE-TOO, 113-114, 114
 HOT trial, 170-173, 172t
 IDNT, 74, 271t
 IRMA 2, 74, 157, 158
 LIFE, 154, 271t
 RENAAL, 74, 154-155
 STOP-Hypertension-2, 119, 120, 270t-271t
 Syst Eur, 169-170
 UKPDS, 115-118, 118t, 173, 186, 270t
 weight loss benefits, 36
 white-coat hypertension and, 25

- Diagnosis of hypertension, 19-30
 ambulatory BP monitoring (ABPM), 25-27
 blood pressure measurements, multiple, 23
 blood pressure thresholds, 27t, 31
 classification of hypertension, 19-21, 21t
 diagnostic evaluation, 27-28, 28t
 diastolic vs systolic BP in, 19-21, 20, 27t
 echocardiogram in, 28-29
 elderly patients, 29
 initial evaluation, 27-28, 28t
 JNC 7 classification, 21-23, 21t
 masked hypertension, 25
 multiple visits/readings for, 25, 26, 31
 overemphasis on numbers, discouragement of, 23
 prehypertension, 21-24, 21t
 pulse pressure and, 24
 references (readings) on, 277-278
 resistant hypertension, diagnosis of, 242-243
 systolic blood pressure and, 19-21, 20, 27t
 vascular resistance studies, 29-30
 white-coat (office) hypertension, 24-25
 young patients (under 15 years), 29
- Diamicron MR, 142-143
- Diastolic blood pressure (DBP). See also *Blood pressure*.
 CV risk and, 19-21, 20
 CV risk, compared to systolic BP, 19, 20
 goal, elderly patients, 265
 J-curve hypothesis and, 64-65
 as prognostic indicator, 24
 thresholds for hypertension definition/treatment, 27t
- Dibenzylidine (phenoxybenzamine), 199
- Diet, 32-34, 32t
 calcium in, 39
 coffee/caffeine in, 46-47
 crash or miracle diets, 32, 33
 DASH diet, 33, 37-38, 38t, 42
 high-fiber, low-fat, 42
 low-sodium, 32t, 37-39, 38t
 magnesium in, 40-41
 potassium in, 39-40
 saturated fat, reduction of, 32t, 33
- Dietary Approaches to Stop Hypertension. See *DASH diet/study*.
- Difficult to control hypertension, 237-252. See also *Resistant hypertension*.
- Digitalis, 225
 hypokalemia in patients on, 88
- Dihydropyridine CCBs, 165, 166t, 167-169. See also *Calcium channel blockers (CCBs)*.
 action mechanisms, 165, 166t, 167
 agents, specific, 165, 166t, 167
 compared with other antihypertensive medications, 271t
- Dihydropyridine CCBs (*continued*)
 contraindications and cautions, 167
 dosage, 166t
 effectiveness of, 167
 long-acting formulations, 167
 short-acting formulations, 167
 trials and studies
 AASK, 75, 179
 ALLHAT, 270t
 ASCOT, 69-70, 176-179, 178t
 HOT, 170-173, 171t, 172t
 INSIGHT, 175, 176, 270t
- Dilacor XR, 165, 166t. See also *Diltiazem*.
- Diltiazem (Cardizem, Dilacor, Tiazac), 165, 166t
 action mechanisms, 165, 166t
 CAPPP study, 114
 dosage, 166t
 effectiveness of, 167
 indications and contraindications for, 218t
 NORDIL trial, 74, 175, 176, 270t
 side effects, 166t, 174, 176
- Diltiazem XR. See *Diltiazem (Cardizem, Dilacor, Tiazac)*.
- Diovan. See *Valsartan*.
- Diovan HCT, 106t, 150, 233t
- Direct renin inhibitors, 110, 161-163. See also *Renin inhibitors*.
- Direct vasodilators, 211-213, 212t, 226t. See also *Vasodilators*.
- Diulo. See *Metolazone*.
- Diuresis, 106t, 235t
- Diuretics, 79-108, 80t-81t, 226t. See also *Loop diuretics; Thiazides; and specific drugs*.
 α_1 -blockers vs, 228, 271t
 ACE inhibitors vs, 91, 216, 271t
 ACCOMPLISH, 133-135, 135t, 136, 270t-271t
 ALLHAT trial, 60, 67, 72-74, 91, 119-130, 271t
 ANBP 2 study, 130-133, 132t, 271t
 ASCOT, 271t
 CAPPP, 114-115
 ACE inhibitors with, 67, 72, 83, 135, 145, 151, 228
 combination medications, 233t
 action mechanisms, 82-85, 83, 84
 action sites, 82
 agents used in hypertension treatment, 80t-81t
 aldosterone antagonists with, 81t
 aliskiren with, 161
 ALLHAT trial, 66-67, 103, 104, 119-130, 270t-271t
 ARBs with, 149-150
 combination medications, 233t
 β -blockers vs, 271t
 β -blockers with, 85, 192, 232, 270t-271t
 combination medications, 234t
 in black patients, 60, 85, 222t, 223

Diuretics (*continued*)

blood pressure decrease with, 85
cardiovascular morbidity and mortality, 65-66, 216, 269
CCBs vs, 175, 216, 228, 269, 270t, 272
central agonists with, 207
chlorthalidone vs HCTZ, 108
cholesterol level and, 90-91, 92t-93t, 94
classes of, 79
combination therapy, 62, 65, 67, 72, 76, 85, 105, 106t, 211, 230-231
 combination medications, 79, 88-90, 106t, 233t-234t
 outcome comparisons, 270t-271t
 three-drug combinations, 230, 234t
contraindications and cautions, 222t-223t
in diabetes, 94-101, 217
dosage, 80t-81t, 85
duration of action, 79, 80t-81t
effectiveness of, 79, 80t-81t
 percentage of patients responsive to, 83-84
in elderly patients, 85, 222t
glucose metabolism and, 91-101, 96t-97t
gout and, 102, 222t, 224
HAPPHY study, 96t
in heart failure treatment, 75
hemodynamic effects of, 83, 83
hypercalcemia and, 87t, 102
hyperlipidemia/hyperglycemia and, 87t, 224
indications for, 65, 71, 222t-223t, 223
 specific or compelling reasons, 67, 68t, 218t-219t
indoline derivatives, 79, 105-107
as initial therapy, 60, 61t, 65-67, 71, 73t, 76, 216-217, 223, 223t, 225
 dosage, 225
 ESH/ESC recommendation, 73t
 JNC 7 recommendation, 65, 67, 73t
 specific or compelling reasons, 218t-219t
 treatment algorithm, 71, 227
lipid levels and, 220, 224
loop, 79, 80t, 107-108
metabolic changes with, 86-102, 87t
monotherapy with, 105, 227
myocardial infarction and, 228, 272
in osteoporosis, 102, 223t
physiologic effects of, 84, 226t
potassium-sparing, 40, 79, 81t, 106t
RAAS stimulation by, 83
reserpine with, 204, 211
side effects, 85-102
 hypercalcemia, 87t, 102
 hyperlipidemia, 87t, 90-91, 92t-93t
 hyperuricemia, 87t, 102
 hypokalemia, 87t, 88-90
 insulin resistance, 87t, 91-101

Diuretics, side effects (*continued*)

renal disease, 102, 103, 104
sexual dysfunction, 86
specific or compelling reasons for use, 67, 68t, 218t-219t
thiazide/thiazide-type, 65, 79, 80t, 223
vasodilation and, 82-83, 213

Diuril. See *Chlorothiazide*.

Dizziness

ACEIs and, 137

CCBs and, 173

Doxazosin (Cardura), 199, 202t. See also *α_1 -Blockers*.

ALLHAT trial, 66, 123

cautions for, 201

diuretic vs, 66

heart failure incidence with, 201

for prostatic hypertrophy, 86

side effects, 200

TOMHS study, 61t

Drug treatment of hypertension, 51-78, 215-236. See also *specific drugs and drug types*.

beneficial effects of long-term therapy, 57-60, 58, 253-275

blood pressure goals, 62, 65

blood pressure lowering as basis of benefits, 70, 72-73, 75, 77-78, 216

cardiovascular morbidity/mortality and, comparative outcome data,

270t-271t

choice of therapy, 60, 75-78, 223-229

combination therapy, 62, 70-72, 215-236

advantages of, 70, 229-231

adverse reactions minimized with, 229

combination medications, 106t, 230-231, 233t-235t

follow-up for, 229-230

indications for, 67, 70-72, 71, 73t, 76-77, 135-137, 225-228, 231

as initial therapy, 70-72, 71, 73t, 225, 227, 231-232

outcome comparison, 270t-271t

three-drug regimens, 90, 230, 234t

vs sequential monotherapy, 60, 70, 72, 229-230

comparative outcome data for antihypertensive medications, 270t-271t

contraindications for, 218t-219t. See also *specific drugs*.

cost and, 63, 76, 221, 269

in diabetic patients, 54-57

factors influencing choice of, 75-78, 223-229, 269

factors influencing outcomes, 60-63

follow-up/monitoring, 62-63

guidelines for, 65-72, 68t

history of, 215

ideal medication characteristics, 217t, 220-221

indications for, 47-48, 51-54, 53t, 55t, 56t

initial therapy, 56t, 60-72, 61t, 71, 73t, 223-229, 227, 267, 267-272

age and race in, 226t

algorithm for, 71, 227

combination therapy recommendations, 67, 70, 71, 73t, 76-77, 215-236, 225, 227, 230-231

Drug treatment of hypertension, initial therapy (*continued*)

- diuretic or diuretic combination as, 60, 61t, 65-67, 71, 73t, 76, 216-217
- in elderly patients, 264-265, 266
- European guidelines, 47-48, 67, 70-72, 73t, 130, 216, 264
- factors influencing choice of, 75-78, 223-229, 231, 269
- ideal medication characteristics, 217t, 220-221
- JNC 6 recommendations, 215-216
- JNC 7 recommendations for, 65-67, 73t
- monotherapy, 70, 72, 215-216, 222t-223t, 227
- multiple drugs for, 70, 71, 76-77
- multiple drugs vs sequential monotherapy, 70, 72, 76-77, 229-230
- risk factors and, 53t, 55t, 56t
- selection of drugs, 215-229
- special situations/specific and compelling reasons, 67, 68t, 73t, 218t-219t, 227
- specific indications and cautions, 218t-219t, 227
- suggested approach, 71, 73t
- summary of recommendations, 75-76
- timing of, 51, 53-54, 71
- trial data and, 72-75, 130
- J-shaped curve, reconsideration of, 64-65
- key points in, 59, 275
- monotherapy, 60, 70, 72, 215-216, 222t-223t
- new-onset diabetes from. See *Diabetes, new-onset*.
- patient education, 63
- physiologic characteristics of drugs, 226t
- references (readings) on, 279-282
- results of, 253-275
 - cardiovascular events, decrease in, 253-261
 - congestive heart failure (CHF), 256, 259-260, 259t
 - coronary heart disease (CHD), 253, 254, 255t, 256, 256t, 257t
 - elderly patients, 261-265, 262t, 263
 - left ventricular hypertrophy (LVH), 258-259, 259t
 - newer comparative trials, 260-261
 - progression of hypertension, 258, 258t
 - references (readings) on, 282-286
 - stroke and MI, 253, 254, 255t, 256
 - summary of trial outcomes, 267-272
 - very old patients, 266-267, 268t
- risk factors and, 51, 53t, 55t, 56t
- side effects, discontinuation due to, 60
- specific drug therapy, 65-72, 68t
- stepped-care, 215
- timing of, 51
 - timing for initiation, 31, 51, 71
- titration of dose, 62, 71
- tolerability of, 76
- WHO-ISH recommendations, 70, 78

Dry mouth, 209

Dyazide, 79, 225, 235t

DynaCirc CR. See *Isradipine*.

Dyrenium (triamterene), 81t

Dyslipidemia. See *Hyperlipidemia; Hypertriglyceridemia; Lipid levels*.

Dyspnea, β -blockers and, 188t

Echocardiogram, 28-29

Edarbi (azilsartan medoxomil), 147, 148t, 149, 217

Edarbyclor (azilsartan medoxomil with chlorthalidone), 106t, 108, 150, 233t

Edema, peripheral, CCBs and, 173, 174

Education, patient, 63

Elderly patients

- ACE inhibitors in, 139, 222t, 223, 225
 - as alternative or add-on therapy, 265
 - side effects, 138
 - STOP-Hypertension-2 study, 119, 120, 264
- ARBs in, 151-152, 222t, 223, 225
 - as alternative or add-on therapy, 265
- β -blockers in, 185, 192, 223, 262-263
 - as third- or fourth-step, 263
- β -blockers with vasodilating properties, caution for, 196
- blood pressure goal in, 62, 265
- cardiovascular risk reduction, trial data, 268t
- CCBs in, 76, 85, 159, 167, 168, 169, 222t, 225, 263
 - ASCOT trial, 176-179, 178t, 264-265
 - as initial therapy, 170, 179, 222t
- combination therapy in, 265
- congestive heart failure in. See *Congestive heart failure*.
- contraindications and cautions, 196
- cost of drugs and, 76
- CV risk and, 52
- diabetes in, 263
- diagnosis in, 29
- diuretics in, 60, 85, 222t
 - as preferred initial therapy, 60
- drug therapy, 62, 223
 - approach to treatment, 265, 266
 - benefits of, 261-265, 262t, 263
 - blood pressure goals, SBP and DBP, 265
 - combination therapy, 265
 - initial therapy, 222t, 223-229, 264-265
 - preferred initial treatment, 223, 264-265
 - J-curve hypothesis, 64
 - references (readings) on, 287-288
 - results of treatment, 261-265, 262t, 263
 - very old patients, 266-267, 268t
- hypokalemia in, 88
- isolated systolic hypertension in, 62
 - case study, 239-241
- memory loss and dementia, reduction in, 159, 170
- percentage with hypertension, not treated, 20-21, 21
- prostatic hypertrophy, 86
- pulse pressure and, 24

- Elderly patients (*continued*)
 resistant hypertension in, 248
 sodium restriction/salt sensitivity in, 27
 trials and studies, 261-265, 262t, 268t. See also *specific studies*.
 ALLHAT, 125
 ASCOT, 176-179, 178t, 264-265
 Australian, 262t
 C & W, 262t
 ELITE 2, 152
 EWPHE, 96t, 262t, 268t
 HDFP, 262t
 HYVET, 107, 262t, 263, 268t
 MRC, 186, 262t, 271t
 SCOPE, 158-159, 170, 264
 SHEP, 170, 261, 262t, 263, 268t
 STOP-Hypertension-2, 72, 119, 120, 262t, 264, 268t
 Syst Eur, 67-69, 169-170, 262t, 264, 268t
 TONE, 37
 VALUE, 159
 very old patients, 266-267, 268t
- Electrocardiogram (ECG), 27, 28t
- ELITE 2 (Evaluation of Losartan in the Elderly-Part 2), 152
- Enalapril (Vasotec), 111t, 135
 ABCD study, 143-144, 144t
 average blood pressure change in TOMHS study, 61t
 in combination therapy, 169
 dosage, 111t, 135
 as monotherapy, 60
 side effects, 111t
 Syst Eur trial, 169
- Enalapril with felodipine (Lexxel), 234t
- Enalapril with hydrochlorothiazide (Vaseretic), 106t, 233t
- Eplerenone (Inspra), 81t, 82, 90, 225, 232
- Eprosartan mesylate (Teveten), 147, 148t
- Eprosartan mesylate with HCTZ (Teveten HCT), 150, 233t
- ESH/ESC. See *European Societies of Hypertension and Cardiology (ESH/ESC)*.
- European Societies of Hypertension and Cardiology (ESH/ESC)
 on blood pressure lowering as basis of drug benefit, 78
 on combination therapy, 73t, 216
 guidelines for monitoring/treatment, 47-48, 70-72, 73t, 216
 hypertension classification, 23
 on initial therapy, 47-48, 67, 73t, 130, 216, 228, 264
- European Working Party on High Blood Pressure in the Elderly.
 See *EWPHE study*.
- Evaluation of Losartan in the Elderly-Part 2. See *ELITE 2*.
- EWPHE (European Working Party on High Blood Pressure in the Elderly)
 study, 96t, 268t
- Exercise, 43-44, 46
 blood pressure reduction from, 44
 caloric expenditure in, 35t, 44
- Exforge, 234t
- Exforge HCT, 234t
- FACET (Fosinopril vs Amlodipine Cardiovascular Events Trial), 74, 143, 270t
 morbidity/mortality outcome data, 143, 270t
- Fat intake, 32t, 33, 42
- Fatigue
 β-blockers and, 188t, 190
 central agonists and, 209
- Felodipine (Plendil), 165, 166t
 action mechanisms, 165, 166t, 167
 dosage, 166t
 HOT trial, 170-173, 171t
 side effects, 166t
- Felodipine with enalapril (Lexxel), 234t
- Fiber, high-fiber diets, 42
- Fibric acid derivatives, 56-57
- Fish oil intake, 32t, 42
- Fitness. See *Exercise*.
- Follow-up recommendations, 47-49, 62-63, 229-230
- Fosinopril (Monopril), 111t
 dosage, 111t
 FACET trial, 143
 side effects, 111t
- Fosinopril with thiazide (Monopril HCT), 233t
- Fosinopril vs Amlodipine Cardiovascular Events Trial (FACET), 74, 143, 270t
- Framingham risk calculation, 48, 52, 53t
- Framingham Study, 19
- Furosemide (Lasix), 80t, 107, 108
 dosage and duration of action, 80t
 for vasodilator-induced fluid accumulation, 213
- Garlic intake, 42
- GEMINI (Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives), 197
- Glucose metabolism. See also *Diabetes; Insulin resistance*.
 diuretics and, 91-101, 96t-97t
 Gout, diuretics and, 102, 222t, 224
 Guanadrel (Hylorol), 203, 205t
 Guanethidine (Ismelin), 203, 205t
 Guanfacine (Tenex). See also *Central agonists*.
- Gynecomastia, 232
- Hair loss, on β-Blockers with vasodilating properties, 195
- HAPPHY (Heart Attack Primary Prevention in Hypertension) study,
 96t, 185
- Harris poll, 273, 274t
- HCTZ. See *Hydrochlorothiazide (HCTZ; Hydrodiuril, Microzide)*.
- HDFP (Hypertension Detection and Follow-up Program), 26, 91
 diabetes, new-onset, 95, 99t
 diuretics and cholesterol levels, 91, 92t, 94
 diuretics and glucose metabolism, 96t

- HDL. See *High-density lipoprotein*.
- Headache
 CCBs and, 173, 174
 vascular (migraine), drug indications for, 222t
- Heart Attack Primary Prevention in Hypertension. See *HAPPHY study*.
- Heart attack. See *Myocardial infarction*.
- Heart disease. See also *Cardiovascular (CV) risk; Cardiovascular morbidity and mortality; Coronary heart disease (CHD); Left ventricular entries*.
 ischemic, 64. See also *Ischemic heart disease*.
- Heart failure
 ACE inhibitors and, 109-114, 216
 HOPE trials, 112-114
 UKPDS, 118t
 on ALLHAT, 125, 127, 129, 168, 271t
 ARBs and, 152
 congestive. See *Congestive heart failure*.
 diuretics and, 75
 drug indications and contraindications in, 67, 68t, 227
 reduced incidence with long-term antihypertensive drug treatment, 58, 59
 specific drug indications, 227
 Val-HeFT study of, 152
- Heart Outcomes Prevention Evaluation (HOPE). See *HOPE; HOPE-TOO*.
- Heart rate, effects of specific antihypertensive drugs on, 226t
- Hemolytic anemia, 209
- High-density lipoprotein (HDL), 55
 α_1 -blockers and, 201
 β -blockers and, 189t
 effects of specific antihypertensive drugs on, 226t
- High-normal hypertension. See *Prehypertension*.
- History of hypertension management, 215
- Home monitoring of blood pressure, 26-27, 63
- HOPE (Heart Outcomes Prevention Evaluation), 75, 90, 112-113, 139
 drug investigated (ramipril), 112
- HOPE-TOO, 113-114, 114
- HOT (Hypertension Optimal Treatment) trial, 170-173, 171t, 172t
 aspirin recommendation from, 173
 blood pressure lowering on, 170-172, 171t, 172t, 273
 cardiovascular events and, 57, 64, 69, 172-173
 outcomes on, 273-275
 summary, 172t
- Hydralazine (Apresoline), 211, 212t, 213. See also *Vasodilators*.
 in ALLHAT trial, 123
 in combination, 211
 dosage, 212t, 213
 indications for, 213, 213t
 physiologic effects, 212t
 side effects, 212t, 213
- Hydrochlorothiazide (HCTZ; Hydrodiuril, Microzide), 79, 80t, 85.
 See also *Thiazides*.
 aliskiren with, 161
 chlorthalidone vs, 108
- Hydrochlorothiazide (HCTZ; Hydrodiuril, Microzide) (*continued*)
 combination therapy, 83
 combination medications, 150, 233t-234t
 three-drug combinations, 230, 234t
 dosage, 85, 225
 duration of action, 79
 ventricular ectopy with, 88, 89, 89t
- Hydrodiuril. See *Hydrochlorothiazide*.
- Hydropres, 204, 235t
- Hylorel (guanadrel), 203, 205t
- Hypercalcemia, diuretic-induced, 87t, 102
- Hyperglycemia, 101
- Hyperlipidemia. See also *Cholesterol; Hypertriglyceridemia; Lipid levels*.
 diuretics and, 87t, 90-91, 92t-93t, 224, 263
 omega-3 fatty acid intake and, 42
 as risk factor, treatment initiation and, 51
- Hypertension. See also *Stage 1 hypertension; Stage 2 hypertension*.
 blood pressure thresholds for, 19, 21t, 27t, 31
 classification of, 19-21, 21t
 definition of, 19-20, 21t, 27t
 JNC 7 definition, 21, 21t
 prehypertension, 21-24, 21t
 progression of, effect of treatment on, 258, 258t
 resistant, 237-252
 results of therapy, 253-275
 secondary causes of, 241, 244t-245t
 severe, 23
 Stage 1, 21t, 48
 Stage 2, 21t
- Hypertension Detection and Follow-up Program. See *HDFP*.
- Hypertension Education Foundation, 63
- Hypertension in the Very Old Trial (HYVET), 107, 262t, 263, 266-267, 268t
- Hypertension Optimal Treatment (HOT) trial. See *HOT trial*.
- Hyperthyroidism, resistant hypertension and, 245t
- Hyperuricemia, diuretic-induced, 87t, 102
- Hypoglycemia, β -blockers and, 191
- Hypokalemia, diuretic-induced, 87t, 88-90
- Hypotension, postural
 ACEIs and, 137
 CCBs and, 173, 174
 peripheral adrenergic inhibitors and, 203
- Hytrin. See *Terazosin*.
- HYVET (Hypertension in the Very Old Trial), 107, 262t, 263, 266-267, 268t
- Hyzaar, 106t, 150, 233t
- IDNT (Irbesartan Diabetic Nephropathy Trial), 74, 155-157, 156, 271t
 morbidity/mortality outcome data, 271t
- Indapamide (Lozol), 79, 80t, 105-107
 ADVANCE trial, 142
 PROGRESS study, 105-107, 133, 134
- Inderal LA. See *Propranolol LA*.

Indoline derivative diuretics, 79, 105-107
 Initial therapy. See *Drug treatment for hypertension, initial therapy*.
 INSIGHT (International Nifedipine Gastrointestinal Therapeutic System Study Intervention as a Goal for Hypertension Therapy), 74, 175, 176, 270t
 diabetes, new-onset, 98t
 Insomnia, β -blockers and, 188t
 Inspra (epplerenone), 81t, 82, 90, 225, 232
 Insulin resistance
 ACE inhibitors and, 139
 diuretics and, 87t, 91-101
 International Nifedipine Gastrointestinal Therapeutic System Study
 Intervention as a Goal for Hypertension Therapy. See *INSIGHT*.
 International Verapamil SR/Trandolapril Study. See *INVEST*.
 Intrinsic sympathomimetic action (ISA), 182t, 183-184
 INVEST (International Verapamil SR/Trandolapril Study), 175-176, 270t
 diabetes, new-onset, 98t
 morbidity/mortality outcome data, 270t
 Irbesartan (Avapro), 147, 148t
 dosage, 148t, 149
 IDNT study, 74, 155-157, 156, 271t
 IRMA 2 study, 74, 157, 158
 Irbesartan with HCTZ (Avalide), 106t, 150, 233t
 Irbesartan Diabetic Nephropathy Trial (IDNT), 74, 271t
 Irbesartan Microalbuminuria Type 2 Diabetes in Hypertensive Patients (IRMA 2), 74, 157, 158
 IRMA 2 (Irbesartan Microalbuminuria Type 2 Diabetes in Hypertensive Patients), 74, 157, 158
 ISA (intrinsic sympathomimetic action), 182t, 183-184
 Ischemic heart disease
 β -blockers and, 185-186, 186t
 DBP reduction and, 64-65
 ISH. See *Isolated systolic hypertension (ISH)*.
 Ismelin (guanethidine), 203, 205t
 Isolated systolic hypertension (ISH), 20
 borderline, 20
 CCBs for, 67
 diuretics for, 67
 elderly patients with, 62
 case study, 239-241
 Syst Eur trial, 67-69
 medication recommendations for, 227
 Isoptin. See *Verapamil*.
 Isradipine (DynaCirc CR), 165, 166t, 174
 action mechanisms, 165, 166t, 167
 dosage, 166t
 MIDAS study of, 270t
 side effects, 166t, 174
 trials of, 175

 J-shaped curve, 64-65
 JNC 6, drug treatment recommendations, 215-216

JNC 7. See *Joint National Committee (JNC 7) recommendations*.
 Joint National Committee (JNC 7) recommendations, 21-23, 21t
 on drug therapy, 65-66, 69t
 current recommendations, 65-66
 initial therapy, 65-66, 69t, 73t
 special situations/specific and compelling reasons, 67, 68t
 on echocardiogram, 28
 on hypertension classification, 21-23, 21t
 on magnesium supplementation, 41

Ketosis, 33

Kidney, nerves to, 248, 249

Kidney disease. See also *Nephropathy; Renal entries*.
 drug indications in, 67, 68t

Labetalol (Normodyne, Trandate), 193, 194t, 196
 dosage, 194t

 indications and contraindications for, 219t
 intravenous, 196

Laboratory work, in initial evaluation, 27-28, 28t

Lasix. See *Furosemide*.

LDL (low-density lipoprotein), 55-56, 226t

Left ventricular dysfunction, white-coat hypertension and, 24

Left ventricular hypertrophy (LVH)

 ARBs and, 152-153, 153t, 157

 CCBs and, 167

 decline in occurrence of, 258-259, 259t

 drug therapy and, morbidity reduction with, 58, 59, 257

 echocardiogram as indicator of, 28

 LIFE study, 75

 masked hypertension and, 25

 prevention of, 258-259, 259t

Levatol (penbutolol), 182t

Lexxel, 234t

LIFE (Losartan Intervention for End-point Reduction in Hypertension)
 study, 152-153, 153t, 271t

β -blockers and, 186, 271t

 diabetes, new-onset, 98t, 154

 left ventricular hypertrophy, 75

 morbidity/mortality outcome data, 271t

Lifestyle modifications, 31-49, 32t, 55t

 alcohol intake/moderation, 32t, 43, 45-46

 blood pressure reduction from, 31, 36, 36t, 42, 49

 body weight, ideal, 32-33, 33t

 calcium supplementation, 39

 cardiovascular risk reduction with, 32t, 33, 38, 43

 coffee/caffeine intake, 46-47

 DASH diet, 33, 37-38, 38t, 42

 exercise, 43-44, 46

 fat intake, 32t, 33, 42

 fiber (high-fiber diets), 42

- Lifestyle modifications (*continued*)
- fish oil intake, 42
 - follow-up program, 47-49
 - garlic intake, 42
 - indications for, 31, 47, 51, 53t, 54, 55t
 - as initial treatment, 20
 - for isolated systolic hypertension, 20
 - magnesium supplementation, 40-41
 - medical treatment in addition to, 31, 49
 - omega-3 fatty acids, 42
 - potassium supplementation, 39-40, 41t
 - for prehypertension, 20
 - references (readings) on, 278-279
 - relaxation programs/biofeedback, 44, 45t, 46
 - smoking cessation, 32t, 46
 - sodium restriction, 37-39, 38t, 45
 - summary of, 45-46
 - timing of initiation, 31, 45, 47
 - timing of treatment, 47-48
 - in treatment algorithm, 71, 227
 - vegetarian diet, 32t
 - weight loss, 31-36, 35t, 36t, 45
- Lipid levels, 27, 46, 220, 226t. See also *Cholesterol*; *Hyperlipidemia*; *Hypertriglyceridemia*.
- ALLHAT trial. See *ALLHAT*.
- α_1 -blockers and, 201
 - β -blockers and, 189t, 190, 220, 224-225
 - diuretics and, 220, 224
 - lipid abnormalities, 55-57
 - lipid management guidelines, 57
 - omega-3 oil intake and, 42
- Lipid solubility, of β -blockers, 184
- Lisinopril (Prinivil, Zestril), 106t, 111t, 135
- aliskiren with, 161
 - ALLHAT trial, 66, 123, 126-129, 130, 141, 168, 269
 - CALM study, 154
 - cardiovascular/coronary heart disease events (ALLHAT), 141, 269
 - cholesterol and, 91
 - dosage, 111t, 135
- Lisinopril with thiazide (Prinzide, Zestoretic), 106t, 233t
- Liver disease, drug indications and contraindications, 219t
- Loniten. See *Minoxidil*.
- Loop diuretics, 79, 80t, 107-108. See also *specific drugs*.
- action mechanism, 79
 - action site, 82
 - dosage, 80t
 - duration of action, 80t
 - indications for, 219t, 223t
- Lopressor. See *Metoprolol*.
- Lopressor HCT, 106t, 192, 234t
- Losartan Intervention for End-point Reduction in Hypertension (LIFE) study, 152-153, 153t
- left ventricular hypertrophy, 75
- Losartan potassium (Cozaar), 147, 148t
- dosage, 148t, 149
 - ELITE 2 trial, 152
 - RENAAL study of, 149, 154-155
- Losartan with thiazide (Hyzaar), 106t, 150, 233t
- Lotensin (benazepril), 111t
- Lotensin HCT, 106t, 233t
- Lotrel, 234t
- Low-density lipoprotein (LDL), 55-56, 90-91
- Lozol (indapamide), 80t
- LVH. See *Left ventricular hypertrophy (LVH)*.
- Macular rash, 137
- Magnesium intake/supplementation, 32t, 40-41, 45
- Malignant hypertension, 18
- Management of hypertension, 17-18. See also *specific topics and drugs/drug classes*.
- algorithm for suggested approach, 71, 227
 - clinical trials. See *Trials and studies*.
 - drug therapy, 51-78, 215-236. See also *Drug treatment of hypertension*.
 - European guidelines, 47-48, 67, 70-72, 228
 - follow-up in, 47-49, 62-63, 229-230
 - history of, 215
 - lifestyle modifications, 31-49. See also *Lifestyle modifications*.
 - physician experience and knowledge in, 272-275
 - resistant hypertension, 241-252, 246-247
- MAPHY (Metoprolol Atherosclerosis Prevention in Hypertension) study, 92t, 185
- Masked hypertension, 25
- Mavik. See *Trandolapril*.
- Maxzide, 79, 225, 235t
- Medical Research Council studies. See *MRC (Medical Research Council) studies*.
- Meditation, 44
- Metabolic syndrome, ACE inhibitors and, 139
- Methyldopa (Aldomet), 207, 208t, 209. See also *Central agonists*.
- in ALLHAT trial, 123
 - contraindications, 219t
 - dosage, 208t, 209
 - indications in pregnancy, 210
- Metolazone (Microx, Zaroxolyn), 80t, 107
- for vasodilator-induced fluid accumulation, 213
- Metoprolol Atherosclerosis Prevention in Hypertension (MAPHY) study, 185
- Metoprolol (Lopressor, Toprol-XL), 182t, 184, 192
- AASK study, 179, 186
 - action mechanism, 181-183, 182t
 - congestive heart failure and, 224

- Metoprolol (Lopressor, Toprol-XL) (*continued*)
 dosage, 182t
 GEMINI study, 197
 lipid solubility, 184
 MAPHY study, 185
 Metoprolol XR, 182t
- Metoprolol with thiazide (Lopressor HCT), 106t, 192, 234t
- Micardis (telmisartan), 147, 148t
- Micardis HCT, 106t, 150, 233t
- Microx. See *Metolazone (Microx, Zaroxolyn)*.
- Microzide. See *Hydrochlorothiazide*.
- Midamor (amiloride), 81t
- MIDAS (Multicenter Isradipine Diuretic Atherosclerosis Study), 270t
- Migraine headache, drug indications for, 222t
- Minipress. See *Prazosin*.
- Minoxidil (Loniten), 211-213, 212t
 contraindications and cautions, 213
 diuretic needed with, 213
 dosage, 212t
 physiologic effects, 212t
 side effects, 211-213, 212t
- Moduretic, 79, 235t
- Moexipril (Univasc), 111t
- Monitoring of blood pressure. See *Blood pressure*.
- Monopril. See *Fosinopril*.
- Monopril HCT (fosinopril with thiazide), 233t
- Mortality data. See *Cardiovascular morbidity and mortality*.
- MRC (Medical Research Council) studies, 96t, 185, 271t
 on β -blockers, 185, 186, 271t
 diuretics and glucose metabolism, 96t, 271t
 diuretics and serum cholesterol, 92t
 on elderly, 186, 271t
- MRFIT (Multiple Risk Factor Intervention Trial), 19, 20
 chlorthalidone vs hydrochlorothiazide outcomes, 108
 diuretics and cholesterol in, 92t
 diuretics and glucose metabolism in, 94, 96t
- Multicenter Isradipine Diuretic Atherosclerosis Study. See *MIDAS*.
- Multiple Risk Factor Intervention Trial. See *MRFIT*.
- Myocardial infarction (MI)
 ACE inhibitors and, 113, 115, 116, 117
 ACE inhibitors vs CCBs, 74, 112, 216, 227, 272
 ARBs and, 153, 153t, 229
 aspirin and, 173
 β -blockers and, 69, 185-186, 186t, 192, 224, 227, 263-264
 CCBs and, 174, 176
 diuretics and, 228, 272
 medications contraindicated after, 218t
 medications indicated after, 67, 68t, 224, 227, 263-264
 nonfatal, on ALLHAT, 270t
 sodium restriction and, 39
- Myocardial infarction (MI) (*continued*)
 trials and studies
 ABCD study, 144, 144t
 ACCOMPLISH, 135t, 136
 ALLHAT, 125, 126, 270t, 272
 HOPE study, 113
 INSIGHT trial, 74, 176, 270t
 SHEP study, 100, 261, 268t
 STOP-Hypertension-2, 119, 121t, 122, 264, 268t, 270t
 UKPDS, 118t
- Nadolol (Corgard), 182t
- Nadolol with bendroflumethiazide (Corzide), 192, 234t
- Nasal drops, 241
- National Cholesterol Education Program, 57
- National Health and Nutritional Examination Studies. See *NHANES*.
- National High Blood Pressure Coordinating Committee, 65
- Nebivolol (Bystolic), 193, 194t, 195-196
 as add-on therapy, 228
 cardiovascular mortality reduction with, 224
 dosage, 194t
- Nephropathy. See also *Kidney disease*; *Renal entries*.
 diabetic. See *Diabetes, nephropathy*.
 IDNT study of, 74, 155-157, 156, 271t
- NHANES (National Health and Nutritional Examination Studies), 273, 274t
- Nicardipine SR (Cardene SR), 166t, 167
- Nicotine, effect on catecholamines, 46
- Nifedipine (Adalat CC, Procardia XL), 166t
 action mechanisms, 165, 166t, 167
 contraindications and cautions, 167
 dosage, 166t
 INSIGHT study, 74, 176, 270t
 longer-acting (Procardia XL), 166t, 174
 physiologic effects, 166t
 side effects, 165, 166t, 176
- Nisoldipine (Sular), ABCD study, 143-144, 144t
- Nitrendipine (Syst Eur trial), 169-170
- Nitric oxide (NO)
 ARBs and, 149
 nebivolol and, 195-196
- NOD (new-onset diabetes). See under *Diabetes*.
- Nondihydropyridine CCBs, 165, 166t, 167. See also *Calcium channel blockers (CCBs)*.
 action mechanisms of, 165, 166t
 agents, specific, 165, 166t
 cardiovascular events and, 167
 combination therapy, 167
 dosage, 166
 indications for, 167
 INSIGHT trial, 74, 175, 176, 270t
 long-acting formulas, 167, 174

- Nondihydropyridine CCBs (*continued*)
 NORDIL trial, 74, 175, 176, 270t
 physiologic effects, 166t
 side effects, 166, 166t, 173-174
- Nondippers, 26
- Nordic Diltiazem (NORDIL) trial. See *NORDIL*.
- NORDIL (Nordic Diltiazem) trial, 175, 176, 270t
 diabetes, new-onset, 98t
 morbidity/mortality outcomes, 74, 270t
 stroke on, 74, 176, 270t
- Normodyne. See *Labetalol*.
- Norvasc. See *Amlodipine*.
- NSAIDs, 241
- Obesity, 31-32, 49. See also *Weight loss*.
 abdominal (visceral), 31
 body shapes in, 31
 comorbidities, 32
 dosage reduction of antihypertensive medication after weight loss, 49
 hypertension and, 32
 incidence in United States, 32, 253-256
 increase in, 253-256
 as risk factor, treatment initiation and, 51
 white-coat hypertension and, 25
- Office hypertension (white-coat hypertension), 24-25
- Olmesartan medoxomil (Benicar), 147, 148t, 149
- Olmesartan medoxomil with amlodipine (Azor), 234t
- Olmesartan medoxomil with amlodipine and hydrochlorothiazide (Tribenzor), 234t
- Olmesartan medoxomil with HCTZ (Benicar HCT), 106t, 150, 233t
- Omega-3 fatty acids, 42
- ONTARGET, 160, 271t
- Oslo studies, 92t, 96t
- Osteoporosis, diuretics and, 102, 223t
- Page, Irvine, 215
- Pancreatitis, 86
- Patient education on drug therapy, 63
- Penbutolol (Levitol), 182t
- Perindopril (Aceon), 111t, 142
- Perindopril Protection Against Recurrent Stroke Study. See *PROGRESS*.
- Peripheral adrenergic inhibitors, 203-204, 205t. See also *specific drugs*.
 drugs in this category, 203, 205t
 physiologic effects, 203, 205t
 side effects, 203-204, 205t
- Peripheral vascular resistance, effects of antihypertensive drugs on, 226t
- Pharmacotherapy. See *Drug treatment of hypertension*.
- Phenoxybenzamine (Dibenzyline), 199
- Phentolamine (Regitine), 199
- Pheochromocytoma, resistant hypertension and, 245t
- Photosensitivity, 86
- Pindolol, 182t, 184
- Plendil. See *Felodipine*.
- Potassium level
 ACE inhibitors and, 109
 aldosterone antagonists and, 232
 dietary, 32t, 39-40, 41t, 45
 diuretic-induced hypokalemia, 87t, 88-90
- Potassium salt substitutes, 40
- Potassium-sparing diuretics, 40, 79, 81t, 106t, 225.
 See also *specific drugs*.
 action mechanism, 79
 action site, 82
 combined with other diuretics, 79
- Potassium supplementation, 39-40
 high-potassium foods, 41t
 recommended dietary intake, 40
 sodium to potassium ratio, 40
 with thiazide diuretics, 40
- Prazosin (Minipress), 199, 202t. See also *α_1 -Blockers*.
 side effects, 199-200
- Pregnancy
 contraindicated drugs, 220t
 ACE inhibitors, 138, 220t, 222t
 ARBs, 138, 220t, 222t
 RAAS inhibitors, 138
 indicated drugs, 210, 220t
 toxemia of, 210, 213t
- Prehypertension, 21-24, 21t
- Preterax, 142-143
- Prinivil. See *Lisinopril*.
- Prinzide, 106t
- Prinzide (lisinopril with thiazide), 106t, 233t
- Procardia XL. See *Nifedipine*.
- PROGRESS (Perindopril Protection Against Recurrent Stroke Study), 72,
 105-107, 133, 134
- Propranolol LA (Inderal LA), 182t, 184
 lipid solubility, 184
- Prostatic hypertrophy
 α_1 -blockers in, 86, 222t
 diuretics and, 86
- Proteinuria, as indicator for treatment initiation, 51, 55, 55t
- Pulse generator, implantation of, 250, 251
- Pulse pressure, as risk criterion, 24
- Quinapril (Accupril), 111t
- RAAS. See *Renin-angiotensin-aldosterone system (RAAS)*.
- RAAS inhibitor. See *Renin-angiotensin-aldosterone (RAAS) inhibitor*.
- Ramipril (Altace), 111t
 AASK study, 75, 179
 aliskiren with, 161

- Ramipril (Altace) (*continued*)
 HOPE and HOPE-TOO studies, 75, 112-114, 114
 ONTARGET, 160
- Rauwolfia alkaloids (Rauzide), 204, 205t
 combined with diuretics, 204
- Rauwolfia serpentina, 205t
- Raynaud's phenomenon, β -blockers and, 183, 188t
- Reduction in Endpoints in Noninsulin-dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan. See *RENAAL*.
- Regitine (phentolamine), 199
- Relaxation programs/biofeedback, 44, 45t, 46
- RENAAL (Reduction in Endpoints in Noninsulin-dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan), 74, 149, 154-155
 end-stage renal disease, 155, 155
- Renal artery disease, 244t
- Renal denervation, 241, 248-250, 250, 275
- Renal disease
 ACE inhibitors and, 138-143, 216, 222t, 261, 269
 ARBs and, 74-75, 222t, 261, 269
 β -blockers and, 191, 269
 CCBs and, 269
 diuretics and, 102, 103, 104, 223t
 drug contraindications, 219t
 drug indications in, 67, 68t, 179, 217
 end stage (ESRD), 155, 155
 ARBs and, 156, 156
 progression to, drug treatment and, 261, 280
 high-potassium diet for, 40
 progression of, drug treatment and, 261, 280
 RAAS inhibitors and, 75
 resistant hypertension and, 244t
 trials and studies
 AASK, 75, 270t
 ADVANCE, 142-143
 IDNT, 74, 155-157, 156, 271t
 IRMA 2, 74, 157, 158
 RENAAL, 74, 149, 154-155
- Renal failure, blood creatine levels in, 246
- Renal function, ACE inhibitors and, 138-143
- Renal insufficiency, drug contraindications in, 219t
- Renal parenchymal disease, 244t
- Renin, 161
- Renin inhibitors, 161-163, 226t, 236
 action mechanism and sites, 110
 combination therapy, 161, 265, 271t
 cautions for, 265
 compared with other antihypertensive medications, 271t
 contraindications, 265
 dosage and physiologic effects, 226t
- Renin-angiotensin-aldosterone (RAAS) inhibitor, 85. See also *ACE inhibitors; Angiotensin II receptor blockers*.
 aliskiren, 161-163
 in combination with diuretic, 60
 contraindications, 76, 265, 271t
 CV morbidity/mortality reduction with, 69, 75
 diabetes and, 75
 diabetes, new-onset, reduction, 75
- Renin-angiotensin-aldosterone system (RAAS)
 diuretics and, 83
 renin inhibitors and, 161, 271t
- Reserpine, 203-204, 205t
 in ALLHAT trial, 123
 combination therapy, 203, 204, 211
 contraindications, 219t
 diuretics with, 204
 dosage, 203-204, 205t
 indications for, 204
 side effects, 203, 205t
- Reserpine with chlorthalidone (Diupres), 106t, 235t
- Reserpine with thiazide (Hydropres), 204, 235t
- Resistant hypertension, 237-252
 case studies, 237-241
 causes of, 237, 241, 244t-245t
 central agonists for, 210
 diagnosis of, 242-243
 diuretics used in, 82
 management approach, 242-243
 secondary causes of hypertension, 241, 244t-245t
 surgical and experimental approaches, 241-252, 250, 251
- Risk factors, treatment initiation and, 47-48, 51, 53t, 56t
- Risk stratification, 52
 Framingham, 48
 treatment choices and, 53t, 56t
- Salt reduction. See *Sodium restriction*.
- SBP. See *Systolic blood pressure (SBP)*.
- SCOPE (Study on Cognition and Prognosis in the Elderly), 158-159, 170, 264
 ARBs and, 158-159
 diabetes, new-onset, 98t, 154
- Sectral. See *Acebutolol*.
- Severe hypertension, 23
- Sexual dysfunction
 β -blockers and, 188t
 diuretics and, 86
 peripheral adrenergic inhibitors and, 203
- SHEP (Systolic Hypertension in the Elderly Program), 170, 261, 268t
 blood pressure lowering on, 273
 blood pressure monitoring in, 26
 cardiovascular events and mortality, 90, 91, 100
 diabetes, new-onset, 95, 98t, 99t, 142

- SHEP (Systolic Hypertension in the Elderly Program) (*continued*)
 diuretics and cholesterol in, 91, 93t
 diuretics and glucose metabolism in, 95, 96t, 98t
 J-shaped curve/DBP in, 64
 outcomes, 261, 263, 268t, 273-275
 Sildenafil (Viagra), 86
 Skin rash, 86
 Sleep apnea, resistant hypertension and, 245t
 Smoking, cessation of, 32t, 46
 Sodium restriction, 32t, 37-39, 45
 average daily intake in United States, 37
 blood pressure reduction from, 37
 DASH diet and, 33, 37-38, 38t
 in elderly and black patients, 37
 high sodium foods (to be avoided), 38t
 myocardial infarction and, 39
 old-style diets, 17
 ratio of sodium to potassium intake, 40
 recommended daily intake, 37, 45
 in renal failure and CHF patients, 38
 salt-sensitive subjects, 37, 39
 salt substitutes (potassium), 40
 TONE study, 37
 Sodium retention, 211
 Spironolactone (Aldactone), 81t, 82, 90, 225, 232
 Spironolactone with hydrochlorothiazide (Aldactazide), 235t
 Stage 1 hypertension, 21t, 48
 drug therapy algorithm, 71
 drug therapy initiation and, 52, 54, 56t, 228
 Stage 2 hypertension, 21t
 combination therapy as initial drug therapy for, 71, 73t, 150-152, 217, 225, 228, 231
 drug therapy algorithm, 71, 227
 drug therapy initiation and, 56t
 Stage 3 hypertension (classification eliminated), 23
 Statins, 56-57
 Stepped-care, 215
 STOP-Hypertension-2 (Swedish Trial in Older Patients with Hypertension), 69, 72, 119, 120, 177, 221, 264, 270t-271t
 β -blockers on, 185
 drugs compared, 119, 221
 frequency of CV events, 119, 120
 mortality and morbidity outcomes, 69, 119, 120, 121t, 122, 268t, 270t-271t
 new-onset diabetes, 98t
 trial description, 119
 Stroke. See also *Transient ischemic attacks*.
 ACE inhibitors, 113, 115, 116, 117, 119, 121t, 125, 128-129
 ACE inhibitors with diuretic, 72
 blood pressure elevation and risk of, 19
 CCBs and, 75, 176, 228, 272
 Stroke (*continued*)
 decline in mortality, associated with antihypertensive treatment, 58, 59, 65, 253, 254, 255t, 256
 prevention, drugs indicated for, 67, 68t
 Syst Eur, 67-69, 264
 trials and studies, 262t
 ACCOMPLISH, 135t, 136, 271t
 ALLHAT, 66, 125, 128, 129, 270t-271t
 CAPPP, 74, 114-115, 116, 117, 270t
 HOPE, 113
 NORDIL, 74, 176, 270t
 PROGRESS, 72, 133, 134
 SHEP, 261, 263, 268t
 STOP-Hypertension-2, 119, 121t, 122, 264, 268t
 Syst Eur, 67-69, 264
 UKPDS, 118t
 Studies. See *Trials and studies*.
 Study on Cognition and Prognosis in the Elderly (SCOPE), 158-159, 170, 264
 Sular. See *Nisoldipine*.
 Surgeries, 17, 248-252
 pulse generator implantation, 250, 251
 renal denervation, 248-250, 250, 275
 Swedish Trial in Older Patients with Hypertension.
 See *STOP-Hypertension-2*.
 Sympathectomy, 17
 Sympathetic innervation of kidney, 248, 249
 Syst Eur (Systolic Hypertension in Europe Multicentre Trial), 67-69, 169-170, 264, 268t
 Systolic blood pressure (SBP), 19-21, 20, 27t. See also *Blood pressure*.
 as accurate predictor of outcomes, 24
 CV risk and, 19-21, 20, 22
 in diagnosis, 19-21, 20, 30
 in elderly patients, 20-21, 21
 goal, elderly patients, 265
 J-curve hypothesis and, 64-65
 lifestyle modifications, reduction with, 36, 36t, 44
 thresholds for hypertension/treatment, 27t, 48
 Systolic hypertension, elderly people, percentage not treated, 20-21, 21.
 See also *Isolated systolic hypertension (ISH)*.
 Systolic Hypertension in Europe (Syst Eur) Multicentre Trial.
 See *Syst Eur*.
 Systolic Hypertension in the Elderly Program. See *SHEP*.
 Tachycardia
 β -blockers and, 185
 dihydropyridine CCBs and, 173, 174
 diuretics and, 88, 89t
 vasodilators and, 211, 212t
 Tadalafil (Cialis), 86
 Tarka, 234t

Taste and appetite loss, ACE inhibitors, 138
 Tekturna (aliskiren), 60, 161-163, 162t
 Telmisartan (Micardis), 147, 148t
 dosage, 148t, 149
 ONTARGET, 160
 Telmisartan with HCTZ (Micardis HCT), 106t, 150, 233t
 Tenoretic, 106t, 192, 234t
 Tenormin. See *Atenolol*.
 Terazosin (Hytrin), 199, 202t. See also *α_1 -Blockers*.
 dosage, 202t
 physiologic effects, 202t
 for prostatic hypertrophy, 86
 side effects, 202t
 Teveten (eprosartan mesylate), 147, 148t
 Teveten HCT (Eprosartan mesylate with HCTZ), 150, 233t
 Thiazides, 79, 80t, 223, 223t. See also *Diuretics*; *specific drugs*.
 action mechanism, 79
 action sites, 82
 ALLHAT trial. See *ALLHAT*.
 ANBP 2 study, 130-133, 132
 dosage, 80t
 drug combinations with, 90
 duration of action, 80t
 hyperglycemia risk, 101
 indications and contraindications for, 71, 223, 223t
 as initial therapy, 71
 loop diuretics vs, 223t
 potassium supplementation with, 40
 side effects. See *Diuretics, side effects*.
 in treatment algorithm, 71
 Tiazac, 165, 166t. See also *Diltiazem*.
 Timolide, 106t
 Timolol with thiazide (Timolide), 106t
 TOMHS (Treatment of Mild Hypertension Study), 48, 61t, 190
 blood pressure change on, 61t
 diuretics and cholesterol in, 92t
 diuretics and glucose metabolism in, 97t
 tolerability of drugs, 76
 TONE (Trial of Nonpharmacologic Interventions in the Elderly), 37
 Toprol-XL. See *Metoprolol*.
 Torsemide (Demadex), 80t, 107
 for vasodilator-induced fluid accumulation, 213
 Toxemia of pregnancy, 210, 213t
 Trandate. See *Labetalol*.
 Trandolapril (Mavik), 111t
 INVEST study, 175-176
 Trandolapril/verapamil XR (Tarka), 234t
 Transient ischemic attacks. See also *Stroke*.
 PROGRESS study, 72, 133, 134
 SHEP study, 261, 263
 Treatment of hypertension. See *Drug treatment of hypertension*;
 Management of hypertension.

Treatment of Mild Hypertension Study. See *TOMHS*.
 Trial of Nonpharmacologic Interventions in the Elderly (TONE), 37
 Trial of Preventing Hypertension (TROPHY), 22
 Trials and studies, 72-75, 216, 267-272, 270t-271t. See also *specific trials and studies*.
 AASK, 75, 145, 179, 186, 270t
 ABCD, 74, 143-144, 144t, 270t
 ACCOMPLISH, 101, 105, 133-135, 135t, 136, 168, 232, 270t-271t
 ACCORD, 65
 ACEIs, 112-137
 ADVANCE, 142-143
 ALLHAT, 66-67, 119-130. See also *ALLHAT*.
 ALTITUDE, 163, 271t
 ANBP 2, 130-133, 132, 271t
 ASCOT, 176-179, 178t, 185, 264-265, 271t. See also *ASCOT*.
 Blood Pressure Lowering Treatment Trialists Collaboration, 69
 C & W (Coope and Warrender), 262t
 CALM, 154
 CAPPP, 114-115, 270t
 CHARM, 98t, 152
 comparative outcome data, 270t-271t
 CONVINCe, 57, 125, 265
 DASH, 37-38, 42
 data influencing current treatment recommendations, 72-75, 216
 ELITE 2, 152
 EWPHE, 96t, 268t
 FACET, 74, 143, 270t
 GEMINI, 197
 HAPPHY, 96t, 185
 HDFP, 26, 91, 94, 95, 96t
 HOPE, 75, 112-113, 139
 HOPE-TOO, 113-114, 114
 HOT, 170-173, 171t, 172t
 HYVET, 107, 262t, 263, 268t
 IDNT, 74, 155-157, 156, 271t
 INSIGHT, 74, 175, 176, 270t
 INVEST, 175-176, 270t
 IRMA 2, 74, 157, 158
 LIFE, 75, 271t
 MAPHY, 185
 MIDAS, 270t
 MRC, 96t, 185, 271t
 MRFIT, 19, 20, 94, 108
 newer comparative trials, 260-261
 NHANES, 273, 274t
 NORDIL, 74, 175, 176, 270t
 ONTARGET, 160, 271t
 Oslo, 92t, 96t
 PROGRESS, 72, 105-107, 133, 134
 RENAAL, 74, 149, 154-155
 SCOPE, 154, 158-159, 170, 264

- Trials and studies (*continued*)
- SHEP, 261, 263, 268t. See also *SHEP*.
- STOP-Hypertension-2, 72, 119, 120, 121t, 122, 185, 264, 268t, 270t-271t
- summary of results and outcomes, 72-75, 216, 267-272, 270t-271t
- comparative outcome data, 270t-271t
- congestive heart failure (CHF), 259-260, 259t
- newer comparative trials, 260-261
- progression of hypertension, 258, 258t
- very old patients, 266-267, 268t
- Syst Eur, 67-69, 169-170, 264, 268t
- TOMHS, 48, 61t, 97t, 190
- TONE, 37
- TROPHY, 22
- UKPDS, 115-118, 118t, 173, 186, 270t
- VA, 76, 86, 97t
- Val-HeFT, 152
- VALUE, 159, 160t
- VHAS, 175, 270t
- Triamterene (Dyrenium), 81t
- Triamterene with hydrochlorothiazide (Dyazide, Maxzide), 79, 235t
- Tribenzor (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 234t
- TROPHY trial, 22
- UKPDS (United Kingdom Prospective Diabetes Study), 72, 115-118, 173, 270t
- β-blockers on, 186, 192
- drugs compared, 115
- morbidity/mortality outcome data, 69, 95, 118t, 267, 270t
- trial description, 115-118
- United Kingdom Prospective Diabetes Study. See *UKPDS*.
- Univasc (moexipril), 111t
- Uric acid, diuretics and, 102, 224
- VA (Veterans Administration) studies, 76, 86, 93t, 97t
- Val-HeFT (Valsartan Heart Failure Trial), 152
- Valsartan (Diovan), 147, 148t. See also *VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial*.
- aliskiren with, 161
- dosage, 148t, 149
- Valsartan Heart Failure Trial (Val-HeFT), 152
- Valsartan with amlodipine (Exforge), 234t
- Valsartan with amlodipine and hydrochlorothiazide (Exforge HCT), 234t
- Valsartan with HCTZ (Diovan HCT), 106t, 150, 233t
- VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial, 72, 140, 159, 160t, 167, 187
- diabetes, new-onset, 95, 98t, 99t, 140, 154
- trial description, 159, 160t
- Vascular resistance, effects of antihypertensive drugs on, 226t
- Vascular resistance studies, 29-30
- Vaseretic, 106t
- Vaseretic (Enalapril with hydrochlorothiazide), 106t, 233t
- Vasodilators, 211-213, 212t, 226t. See also *ACE inhibitors*.
- ACEIs as, 109
- action site of, 110
- ARBs as, 149
- contraindications and cautions, 212t, 213, 218t
- direct vasodilators, 211-213, 212t
- dosage, 212t
- exercise and, 44
- fluid accumulation with, 213
- indications for, 213, 213t
- physiologic effects, 211, 212t, 226t
- side effects, 211, 212t
- Vasotec. See *Enalapril*.
- Vegetarian diet, 32t
- Ventricular ectopy, 88, 89, 89t
- Ventricular function. See *Left ventricular entries*.
- Verapamil (Calan, Covera, Isoptin, Verelan), 165, 166t
- action mechanisms, 165, 166t
- atherosclerosis and (VHAS study), 175, 270t
- dosage, 166t
- effectiveness of, 167
- formulations, 166t
- verapamil-coer (Covera HS, Verelan PM), 166t
- verapamil IM (Calan, Isoptin), 166t
- verapamil LA (Calan SR, Isoptin SR), 166t
- verapamil XR with trandolapril (Tarka), 234t
- indications and contraindications for, 218t
- side effects, 166t, 174
- with trandolapril (INVEST study), 175-176
- Verapamil in Hypertension Atherosclerosis Study (VHAS), 175, 270t
- Verelan. See *Verapamil*.
- Veterans Administration (VA) studies, 76, 86
- VHAS (Verapamil in Hypertension Atherosclerosis Study), 175, 270t
- Viagra (sildenafil), 86
- Visken. See *Pindolol*.
- Weight loss, 31-36, 45
- bariatric surgery for, 33
- blood pressure reduction from, 34-36, 36t
- calories expended in various activities, 35t
- DASH diet, 33, 37-38, 38t
- exercise in, 35t
- high-fat diet, 33
- ideal body weight, 32-33, 33t
- calories needed to maintain, 34, 34t
- for prevention of diabetes and future hypertension, 36
- Whiskey, recommended intake limit, 43
- White-coat hypertension (office hypertension), 24-25, 187
- WHO-ISH (World Health Organization-International Society of Hypertension), 70, 78
- Wine, recommended intake limit, 43

World Health Organization-International Society of Hypertension
(WHO-ISH), 70, 78

Yoga, 44

Zaroxolyn, 80t, 107

Zebeta. See *Bisoprolol*.

Zestoretic, 106t

Zestoretic (lisinopril with thiazide), 106t, 233t

Zestril. See *Lisinopril*.

Ziac, 234t